on-pharmacological techniques for cognitive improvement in schizophrenia
- Conditions
- Schizophrenia
- Registration Number
- RBR-69g952
- Lead Sponsor
- niversidade Federal de São Paulo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Data analysis completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Subjects between 18 to 65 years old diagnosed with schizophrenia; No history of substance abuse/dependence, in exception to tobacco and/or caffeine; No diagnosis of any neurological conditions (e.g. Parkinson’s disease); (d) No history of seizures; No unexplained loss of consciousness; Stability of pharmacological treatment for at least 6 weeks; No contraindications to tDCS, such as metal in the head or implanted brain medical devices; No pregnancy at enrollment; acceptance to participate in the study and provide the written informed consent.
Subjects with psychiatric diagnoses other than schizophrenia, except bu the health controls; Subjects with schizophrenia with predominant positive symptoms; Subject illiterate or unable to complete the cognitive assessment; IQ < 70; Clinically relevant suicide risk. Dropout was considered after absence in two consecutive tDCS sessions
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intended outcome: differences in MATRICS total score, comparing the baseline, after and follow-up measures.;Observed outcome: difference in working memory composite score, measured by the Brazilian version of the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MATRICS). <br>It was compared the baseline, after and follow-up measures.<br>Observed results: no differences were observed for working memory after tDCS, through time*group analysis (p=0.720, IC: 95%)
- Secondary Outcome Measures
Name Time Method